Surfing the MASH Tsunami

Send us Fan Mail This conversation is centered on Marcelo Kugelmas's portion of Madrigal's disease-focused presentation at the Chronic Liver Disease Foundation's LiverConnect meeting this past March in Scottsdale, AZ. Marcelo addresses issues of NAFLD patient screening and NASH patient management. Afterwards, he answers questions and reviews key elements of the presentation with Rog...

Send us Fan Mail This conversation is centered on Mazen Noureddin's portion of Madrigal's disease-focused presentation at the Chronic Liver Disease Foundation's LiverConnect meeting this past March in Scottsdale, AZ. Mazen addresses issues of NAFLD Pathophysiology and NASH epidemiology, after which he answers questions and reviews key elements of the presentation with Roger Green. T...

Send us Fan Mail Louise Campbell starts this discussion by citing her sources of optimism about NASH drug development: (i) the high likelihood of getting a drug to market over the next couple of years, which will lead to better education of patients and providers alike; (ii) FDA looking for more inclusion and diversity about drug trials, which will provide even more information for historically un...

Send us Fan Mail This conversation is part of a broader overview of NASH drug development in 2022, led by Stephen Harrison and Jörn Schattenberg. It starts with Louise Campbell asking whether design and management of the ongoing trials will provide sufficient granularity on matching patient types to medications or drug classes. Stephen Harrison notes that we have not paid sufficient attention to t...

Send us Fan Mail This conversation is part of a broader overview of NASH drug development in 2022, led by Stephen Harrison and Jörn Schattenberg. It starts with Jörn commenting on the exceptional scope of opportunities for deep data dives and new learning, which becomes a lead-in for him to ask Stephen about the scope of data available from Intercept. From there, the group explores a range of issu...

Send us Fan Mail This conversation is part of a broader overview of NASH drug development in 2022, led by Stephen Harrison and Jörn Schattenberg. Stephen starts this conversation by noting that the mechanics of the drug development pathway, which we discussed earlier this year in the context of NASH-TAG and strategies on how to shift away from traditional metrics, remain what they have been: same...

Send us Fan Mail This week, NASH Tsunami responds to listeners who have asked "Where are the episodes on drug development?" by asking Stephen Harrison to lead a review of the NASH pipeline. Stephen starts by noting that the mechanics of the drug development pathway, which we discussed earlier this year in the context of NASH-TAG and strategies on how to shift away from traditional metric...

Send us Fan Mail One of the most intriguing presentations at this month's inaugural Innovations in NAFLD Care 2022 conference (#INCBCN) came from physician, author and entrepreneur Dr. Marcus Ranney. In this conversation, Roger Green interviews Marcus on his experiences unique vision and the future of #biohacking. In this conversation, Marcus discusses his own "journey of figuring out......

Send us Fan Mail On May 6 and 7, over 100 NAFLD stakeholders convened in Barcelona and on-line for the inaugural Innovations in NAFLD Care 2022 conference (#INCBCN.) Surfing the NASH Tsunami was there, with Jörn Schattenberg serving as event co-founder and Louise Campbell and Roger Green moderating sessions. This week's episode is less a formal recap of the meeting than recollections of key m...

Send us Fan Mail On May 6 and 7, over 100 NAFLD stakeholders convened in Barcelona and on-line for the inaugural Innovations in NAFLD Care 2022 conference (#INCBCN.) Surfing the NASH Tsunami was there, with Jörn Schattenberg serving as event co-founder and Louise Campbell and Roger Green moderating sessions. This week's episode is less a formal recap of the meeting than recollections of key m...

Send us Fan Mail On May 6 and 7, over 100 NAFLD stakeholders convened in Barcelona and on-line for the inaugural Innovations in NAFLD Care 2022 conference (#INCBCN.) Surfing the NASH Tsunami was there, with Jörn Schattenberg serving as event co-founder and Louise Campbell and Roger Green moderating sessions. This week's episode is less a formal recap of the meeting than recollections of key m...

Send us Fan Mail On May 6 and 7, over 100 NAFLD stakeholders convened in Barcelona and on-line for the inaugural Innovations in NAFLD Care 2022 conference (#INCBCN.) Surfing the NASH Tsunami was there, with Jörn Schattenberg serving as event co-chair and Louise Campbell and Roger Green moderating sessions. This week's episode is less a formal recap of the meeting than recollections of key mom...

Send us Fan Mail Last week, all three #NASHTsunami co-hosts participated in the inaugural Innovations in NAFLD Care (#INCBCN) 2022 conference in Barcelona. Today, co-chair Jeff Lazarus joins Jörn, Louise and Roger in reviewing the conference's high points and key messages. The meeting itself brought a diverse group of Fatty Liver stakeholders to Barcelona last week to explore NAFLD care from...

Send us Fan Mail The entire Fatty Liver community benefits from NASH Patient Advocacy and the work of our advocates, but relatively few of us understand what advocates do or how we benefit from their work. Leading German patient advocate Achim Kautz and Global Liver Institute Vice President of Policy and Public Affairs Andrew Scott discuss how they came to Fatty Liver patient advocacy, their prior...

Send us Fan Mail The entire Fatty Liver community benefits from NASH Patient Advocacy and the work of our advocates, but relatively few of us understand what advocates do or how we benefit from their work. Leading German patient advocate Achim Kautz and Global Liver Institute Vice President of Policy and Public Affairs Andrew Scott discuss how they came to Fatty Liver patient advocacy, their prior...

Send us Fan Mail The entire Fatty Liver community benefits from NASH Patient Advocacy and the work of our advocates, but relatively few of us understand what advocates do or how we benefit from their work. Leading German patient advocate Achim Kautz and Global Liver Institute Vice President of Policy and Public Affairs Andrew Scott discuss how they came to Fatty Liver patient advocacy, their prior...

Send us Fan Mail The entire Fatty Liver community benefits from NASH Patient Advocacy and the work of our advocates, but relatively few of us understand what advocates do or how we benefit from their work. Leading German patient advocate Achim Kautz and Global Liver Institute Vice President of Policy and Public Affairs Andrew Scott discuss how they came to Fatty Liver patient advocacy, their prior...

Send us Fan Mail The entire Fatty Liver community benefits from NASH Patient Advocacy and the work of our advocates, but relatively few of us understand what advocates do or how we benefit from their work. Leading German patient advocate Achim Kautz and Global Liver Institute Vice President of Policy and Public Affairs Andrew Scott discuss how they came to Fatty Liver patient advocacy, their prior...

Send us Fan Mail The entire Fatty Liver community benefits from NASH Patient Advocates and the work of our advocates, but relatively few of us understand what advocates do or how we benefit from their work. Leading German patient advocate Achim Kautz and Global Liver Institute Vice President of Policy and Public Affairs Andrew Scott discuss how they came to Fatty Liver patient advocacy, their prio...

Send us Fan Mail The 5th Global NASH Congress will take place in London (in person only) on May 27 and 28. Louise Campbell and scientist/entrepreneur Rachel Zayas, who will cover the Congress for NASH Tsunami, join Ian Rowe and regulars Jörn Schattenberg and Roger Green to discuss some key papers and issues covered there. This episode focuses on a range of topics: the importance of weight loss, th...

Send us Fan Mail The 5th Global NASH Congress will take place in London (in person only) on May 27 and 28. Louise Campbell and scientist/entrepreneur Rachel Zayas, who will cover the Congress for NASH Tsunami, join Ian Rowe and regulars Jörn Schattenberg and Roger Green to discuss some key papers and issues covered there. This conversation starts with Ian Rowe and Jörn Schattenberg sharing their p...

Send us Fan Mail The 5th Global NASH Congress will take place in London (in person only) on May 27 and 28. Louise Campbell and scientist/entrepreneur Rachel Zayas, who will cover the Congress for NASH Tsunami, join Ian Rowe and regulars Jörn Schattenberg and Roger Green to discuss some key papers and issues covered there. This conversation starts with comments from Jörn Schattenberg and Ian Rowe t...

Send us Fan Mail The 5th Global NASH Congress will take place in London (in person only) on May 27 and 28. Louise Campbell and scientist/entrepreneur Rachel Zayas, who will cover the Congress for NASH Tsunami, join Ian Rowe and regulars Jörn Schattenberg and Roger Green to discuss some key papers and issues covered there. This episode focuses on issues surrounding gut microbiome, its relationship...

Send us Fan Mail The 5th Global NASH Congress will take place in London on May 26-27. Surfing the NASH Tsunami is serving as a Media Partner for the event. Professor Ian Rowe and scientist/entrepreneur Rachel Zayas join Jörn Schattenberg, Louise Campbell and Roger Green to review some key presentations and discuss what attendees are likely to learn from the Congress. The preliminary agenda for the...

Send us Fan Mail This conversation includes part of a more extended discussion that Donna Cryer had with Louise Campbell and Roger Green when she stopped by the virtual SurfingNASH.com studios to discuss her recent work. It begins with a discussion between Donna Cryer and Louise Campbell, in which Louise discusses the processes and approaches she uses to educate patients. At the same time, she not...